Pembrolizumab as a first-line treatment for advanced gastric cancer
- PMID: 37875145
- DOI: 10.1016/S1470-2045(23)00526-0
Pembrolizumab as a first-line treatment for advanced gastric cancer
Conflict of interest statement
I report personal fees for participation on advisory boards from Eli-Lilly, Bristol Meyers Squibb, MSD, Roche, Merck-Serono, Astra-Zeneca, OncXerna, Boehringer Ingelheim, Incyte, Astella, GlaxoSmithKline, Sotio, Eisai, Daiichi-Sankyo, Taiho, Servier, Seagen, Turning Point Therapeutics, Novartis, BioNTech, and Takeda; research grants from Eli-Lilly and Janssen-Cilag; and honoraria from Eli-Lilly, Eisai, Servier, Roche, and MSD.
Comment on
-
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
